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INTRODUCTION
Gabapentin, a structural analogue to gamma-aminobu-
tyric acid (GABA), is orginally developed as an anticonvul-
sant (1). It has been shown to reverse allodynia and hyperal-
gesia of many pain models in animal studies. Intrathecal
gabapentin attenuates tactile-evoked allodynia in the Chung
model of neuropathy (2) and thermal hyperalgesia in a rat
model of painful peripheral neuropathy (3). Partridge et al.
demonstrates its efficacy on substance-P induced thermal
hyperalgesia (4). In studies on facilitated pain in rats follow-
ing the formalin test, gabapentin suppress the pain behavior
observed during the second phase (5, 6). Furthermore, its
effectiveness for the treatment of neuropathic pain such as
postherpetic neuralgia (7) and complex regional pain syn-
drome (8) has been reported in human studies.
Although some adverse effects have been noted, they were
usually slight and disappeared within 2 weeks without inter-
ruption of the treatment, and the most serious adverse effect
is convulsion (9).
Owing to these advantages and effectiveness, gabapentin
has been widely used in the management of a variety of neu-
ropathic pain, but there are lack of data or information about
its effect on hemodynamics and no known cardiovascular side
effects in human.
Therefore, the purpose of this study was to examine the
changes of hemodynamics following administration of intra-
thecal (IT), intracerebroventricular (ICV), and intraperitoneal
(IP) gabapentin in rats.
MATERIALS AND METHODS
All experiments were reviewed and approved by the Insti-
tutional Animal Care Committee, Research Institute of Med-
ical Science, Chonnam National University. 
Male Sprague-Dawley rats weighing 300-325 g were used.
Rats were housed in groups of 4-6 with free access to food
and water at all times. 
For IT administration of the drug, rats were implanted
with polyethylene (PE)-10 catheter (10). Briefly, under enflu-
rane (3-4%)/O2 anesthesia, the head of rats was placed in a
stereotactic head holder. A skin incision was made along the
dorsum of the skull, and dura mater was exposed by blunt
dissection. The dura was incised, and a polyethylene (PE-10)
catheter was advanced caudally to end at lumbar enlargement.
The external catheter was tunneled under the skin and exit-
ed at the top of the head. 
The ICV route for drug injection was constructed through
skull (11). Placing the rat in a stereotactic holder under enflu-
rane (3-4%)/O2 anesthesia, a burr hole was made at 0.5 mm
caudally from the coronal suture and 1.0 mm laterally from
the sagittal suture. Through this hole, a stainless steel, thin-
walled guide cannula was placed into the ventricle to a depth
of 3 mm from dura mater and affixed to the skull with stain-
less steel screws and cranioplastic cement. 
After surgery, rats were kept in individual cages. Animals
showing neurologic dysfunction postoperatively were sacri-
ficed immediately by excessive enflurane inhalation. Only
rats that displayed no postsurgical motor or sensory deficits
were assessed. Experiments were performed at least 4-5 days
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Hemodynamic Effects of Gabapentin in Rats
Gabapentin has been known to elicit the antinociceptive effect. However, little has
been known about the effect of gabapentin on the cardiovascular system. The author’s
aim of this experiment was to examine the hemodynamic effects of gabapentin. Male
Sprague-Dawley rats were used. Intrathecal or intracerebroventricular catheters were
implanted and gabapentin was delivered through each catheter or directly into the
peritoneal cavity. For hemodynamic measurements, catheters were inserted into
the tail artery. Blood pressure and heart rate were measured over 60 min following
administration of gabapentin. Intrathecal and intraperitoneal gabapentin did not induce
significant changes of hemodynamics over the 60 min compared to the baseline
value. Intracerebroventricular gabapentin increased systolic and diastolic blood pres-
sure, but there is no statistically difference in blood pressure change according to
the dose.
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following IT or ICV implantation. 
For IP administration, the drug was injected into the peri-
toneal cavity directly.
In order to measure hemodynamic changes, a PE-50 catheter
was inserted into the tail artery under enflurane (3-4%)/O2
anesthesia and then the rats were restrained in a restraint
cylinder. The catheter was flushed with 0.5 mL heparinized
saline. The arterial line was connected to a pressure trans-
ducer of monitor (Datex-Ohmeda AS/3, Finland) for con-
tinuous recording of blood pressure and heart rate.
Rats were divided into three groups of IT (n=20), ICV
(n=22), and IP (n=20) according to the route of drug adminis-
tration. Each group was divided into four subgroups accord-
ing to the dose of drug. 
The doses of gabapentin for IT and ICV were 10, 30, 100,
and 300  g, respectively, and those for IP were 10, 30, 100,
and 300 mg/kg, respectively. Gabapentin was dissolved in
physiologic saline. A gear-driven microinjector was used to
deliver the drug in IT and ICV groups, and the drug was
given in 10  L of saline. IT administration was followed by
an additional 10  L of saline to flush the catheter. In the IP
group, the drug was injected into the peritoneal cavity with
a volume of 3 mL/kg through the slit of the restraint cylin-
der. Blood pressure and heart rate were measured at 5, 10,
15, 20, 30, 40, 50, and 60 min after IT and ICV adminis-
tration. After 30 min following IP injection, hemodynam-
ics were measured at the same time intervals. 
All data are presented as means±SEM. Baseline blood
pressure and heart rate were compared by using one-way
ANOVA. Stastistical analysis of hemodynamic changes was
done using two-way repeated-measures ANOVA. A p value
<0.05 was considered statistically significant.
RESULTS
The baseline systolic blood pressure, diastolic blood pres-
sure, and heart rate were 127.8±1.5 mmHg, 92.6±9.4
mmHg, and 416.4±2.9 beats/min, respectively. The base-
line blood pressure and heart rate in the several treatment
groups did not differ. No changes of hemodynamics com-
pared with baseline value were seen over the 60 min-period
following administration of IT and IP gabapentin (Fig. 1, 3).
However, systolic and diastolic blood pressure were gradu-
ally increased compared with baseline blood pressure after
administration of gabapentin in all ICV subgroups (Fig. 2).
And the change of heart rate was not statistically significant.
Although the blood pressure was significantly increased after
ICV injection, the extent of change was not different among
ICV subgroups.
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Fig. 1. Time effect curve of intrathecal gabapentin for systolic
blood pressure (SBP) and diastolic blood pressure (DBP) and
heart rate (HR). Gabapenin was administered at time 0. Each
line represents the mean±SEM of 5-7 rats.
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DISCUSSION
Gabapentin, administered via IT, IP, but ICV routes, did
not affect the blood pressure or heart rate in the present study.
These findings indicate that gabapentin may be given safely
via IT and IP routes  without the change of hemodynamics.
Numerous animal and human studies have shown that
gabapentin is effective in a wide variety of pain syndromes.
In human studies, it consistently provided relief of pain asso-
ciated with various conditions including postherpetic neu-
ralgia (7), diabetic peripheral neuropathy (12), and complex
regional pain syndrome (8). Its efficacy on allodynia and
hyperalgesia was also demonstrated in numerous animal
studies (2-6). In these studies, gabapentin reduced the pain
response of rat paw formalin test, thermal injury model, rat
model of peripheral neuropathy and surgically induced neu-
ropathic pain model.
Although there are many proposals for the mechanism of
action of gabapentin, it has not been fully elucidated. Non-
strychnine site of NMDA receptor and the  2 subunit of
voltage-sensitive calcium channels have been suggested as
the binding site of gabapentin (4, 5, 13). Clinically, the most
common side effects of gabapentin are dizziness, somnolence,
headache, and diarrhea (12). Side effects increase linearly with
the increase of the daily dose, but the relative safety is sup-
ported in many studies including a case report of overdose
of 48.9 g with lack of serious toxicity (14, 15). In addition,
there has been no documentation of side effects on cardio-
Fig. 2. Time effect curve of intracerebroventricular gabapentin for systolic blood pressure (SBP) and diastolic blood pressure (DBP) and
heart rate (HR). Gabapenin was administered at time 0. Each line represents the mean±SEM of 5-7 rats. *Statistically significant com-
pared with baseline value.
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vascular system. 
Although the current study was undertaken on animals,
it showed that neither systemic nor intrathecal gabapentin
affected the hemodynamics. These results are consistent with
the previous findings (5, 6). Furthermore, intraduodenal
gabapentin (100 mg/kg) produced no significant effects on
the mean arterial blood pressure and heart rate (16), although
animals in that study were pretreated with guanethidine and
anesthetized owing to the invasiveness of the study. And 100
mg/kg gabapentin did not change the mean blood pressure
within 60 min after intravenous administration in another
study (17). 
In our study, IT or IP administration of gabapentin did
not affect blood pressure and heart rate. However, systolic
and diastolic blood pressure were increased after ICV admin-
istration. Considering the minimal hemodynamic effect of
IT gabapentin, increased blood pressure in ICV gabapentin
was an unexpected result. Furthermore, dose-dependency was
not observed in the ICV group. This different result might
be related with very low volume of test drug, which could
not have reached the brain when administered intrathecally.
The unknown change of pharmacokinetics of ICV gabapen-
tin could be thought of as one for the result, and the CNS side
effects of gabapentin such as nausea, vomiting and headache
might be attributed to the result. However, the reasons of
these changes of blood pressure without dose-response rela-
tionship are uncertain and further studies for the side effects
of ICV gabapentin including cardiovascular effects are re-
quired. The above mentioned findings jointly suggest that
gabapentin does not affect cardiovascular responses when it
is used via IT or IP but ICV route. Thus, if another prepara-
tion of IT or IP route is developed in the future, albeit only
oral agents are clinically available now, it can be prescribed
safely without cardiovascular side effects. But the result of
increased blood pressure caused by ICV gabapentin suggests
that it should be used cautiously, especially in patients with
cardiovascular disease.
In conclusion, ICV gabapentin increased systolic and
diastolic blood pressure, but IT and ICV gabapentin did
not change hemodynamics.
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